ライフサイエンスコーパス: ABCB1

1 otein MDR1 (also known as P-glycoprotein and ABCB1).

2 ad low affinity toward P-glycoprotein (P-gp, ABCB1).

3 he efflux transporter, P-glycoprotein (P-gp, ABCB1).

4 flux transporter P-glycoprotein (MDR1, P-gp, ABCB1).

5 e also abolishes auxin transport activity by ABCB1.

6 ith the expression level and localization of ABCB1.

7 gene, encoding the multidrug resistance pump ABCB1.

8 ch broader range of cancer drugs effluxed by ABCB1.

9 Ko143, and they are selective for ABCG2 over ABCB1.

10 human counterpart, the MDR1 P-glycoprotein, ABCB1.

11 rane domains, TWD1 colocalizes with nonpolar ABCB1.

12 ghly homologous to the multidrug transporter ABCB1.

13 large cavity of the transmembrane region of ABCB1.

14 that activation of this pathway may restore ABCB1.

15 f ABCB1 and ABCG2, with a stronger effect on ABCB1.

16 haracterize ROR1 as an upstream regulator of ABCB1.

17 ork of enhancers that controls expression of ABCB1.

18 eat (Triticum aestivum) auxin efflux carrier ABCB1.

19 expressing the multi-drug efflux transporter ABCB1.

20 moter strength, and chromosomal proximity to ABCB1.

21 system effects despite being transported by ABCB1.

22 ancer and led to dose-dependent induction of ABCB1.

23 er in ABCB1 1236TT homozygotes compared with ABCB1 1236C carriers and was 12.4% higher in IL-10 -1082

24 ABCB1 1236C>T under the recessive model and IL-10 -1082G

25 Genotyping was performed for ABCB1 1236C>T, 2677 G>T/A, and 3435C>T; CYP3A4 -392A>G;

26 ate-binding cassette, subfamily B, member 1 (ABCB1) 1236C>T, 2677 G>T/A, and 3435C>T, cytochrome P450

27 Mean TG value was 25.1% higher in ABCB1 1236TT homozygotes compared with ABCB1 1236C carri

28 2) = 0.07, p = 1.9 x 10(-11)), whereas PON1, ABCB1 3435 C-->T, and other candidate SNPs were not.

29 Individuals with the ABCB1 3435 TT genotype have reduced platelet inhibition

30 ABCB1 3435C>T and IL-10 -1082G>A were significantly asso

31 ABCB1 3435C>T and IL-10 -1082G>A were significantly asso

32 reviously showed significant associations of ABCB1 3435C>T and IL-10 -1082G>A with log-transformed SR

33 Under the dominant genetic model, ABCB1 3435C>T was associated with TC (P=0.0001) and LDL-

34 In patients treated with clopidogrel, ABCB1 3435C-->T genotype was significantly associated wi

35 Mean SRL C/D was 48% higher in patients with ABCB1 3435CT/TT genotype than those with 3435CC genotype

36 26.9 and 24.9 mg/dL higher, respectively, in ABCB1 3435T carriers than 3435CC homozygotes at an avera

37 d increased in Griptite cells overexpressing ABCB1 (+40.7%; p < 0.05).

38 nor CC genotype at C3435T (rs1045642) within ABCB1, a variant known to alter protein expression, was

39 SLC22A7, SLC47A1, SLCO1B1, SLCO1B3, SLCO2B1, ABCB1, ABCB11, ABCC2, ABCC3, ABCC4, ABCC6, and ABCG2 We

40 triphosphate-binding cassette transporters (ABCB1, ABCB4, and ABCC1) were present.

41 etic polymorphisms in CYP2B6, NR1I3, CYP2A6, ABCB1, ABCB5, and ABCG2.

42 These include ABCA2, ABCB1, ABCB6, ABCC1, ABCC2, ABCC3, ABCC4, ABCC5, ABCC10,

43 s multidrug resistance (MDR) mediated by the ABCB1, ABCC1, and ABCG2 drug-efflux transporters.

44 cts on cell surface ABC transporters such as ABCB1, ABCC1, and ABCG2 that modulate intracompartmental

45 terization of new fluorescent substrates for ABCB1, ABCC1, and ABCG2.

46 mising representative, compound 37, reversed ABCB1-, ABCC1-, and ABCG2-mediated MDR, making it one of

47 more, 11 pyrimidines were revealed as triple ABCB1/ABCC1/ABCG2 inhibitors.

48 ss response (cas8, 14-3-3epsilon, p-38 MAPK, Abcb1, Abcc5) was investigated.

49 ratherapeutic-dose oral erlotinib to inhibit ABCB1/ABCG2 activity at the human BBB.

50 ut its clinical applicability for continuous ABCB1/ABCG2 inhibition at the BBB may be limited by safe

51 We successfully implemented ABCB1/ABCG2 inhibition protocols in nonhuman primates re

52 ib (10 mg/kg) or after pretreatment with the ABCB1/ABCG2 inhibitor elacridar (10 mg/kg).

53 r treatment of brain tumors, but no marketed ABCB1/ABCG2 inhibitors are currently available.

54 ified it as one of the ten best triple ABCC1/ABCB1/ABCG2 inhibitors in the literature.

55 We assessed the efficacy of two different ABCB1/ABCG2 inhibitors to enhance brain distribution of

56 Pharmacologic inhibition of ABCB1/ABCG2 may improve the efficacy of dual-substrate d

57 nib may be used to enhance brain delivery of ABCB1/ABCG2 substrate anticancer drugs, but its clinical

58 ectively restrict brain distribution of dual ABCB1/ABCG2 substrate drugs, such as tyrosine kinase inh

59 Pharmacologic strategies to inhibit ABCB1/ABCG2-mediated efflux transport at the BBB have be

60 Treatment with drugs that induce cerebral ABCB1 activity may be a promising approach to delay the

61 Treatment with drugs which induce cerebral ABCB1 activity may be a promising approach to delay the

62 As an outcome parameter of cerebral ABCB1 activity, the elimination slope of radioactivity w

63 As an outcome parameter of cerebral ABCB1 activity, the elimination slope of radioactivity w

64 of combined partial saturation of ABCG2 and ABCB1 activity.

65 ively characterized MDR transporters include ABCB1 (also known as MDR1 or P-glycoprotein) and ABCC1 (

66 is the overexpression of drug efflux pumps, ABCB1 (also known as MDR1 or P-gp) and ABCC1 (also known

67 The ABC transporter P-glycoprotein (Pgp; ABCB1) also contains a Pim-1 phosphorylation consensus s

68 ABCB1, also known as P-glycoprotein, actively extrudes x

69 DR proteins, MGMT (a DNA repair protein) and ABCB1 (an efflux protein), revealing microRNA-4539 and m

70 ased the expression of P-glycoprotein (P-gp, ABCB1), an ATP binding cassette that is usually associat

71 arvested for immunohistochemical analysis of ABCB1 and AB levels.

72 romosomal region 7q21.12 harbouring both the ABCB1 and ABCB4 genes, with the most notable SNPs after

73 ing the potential functional significance of ABCB1 and ABCB4, underlines the likely importance of the

74 sed ATP-binding-cassette (ABC) transporters, ABCB1 and ABCB5.

75 to paclitaxel because of the upregulation of ABCB1 and ABCB5.

76 stigations of the inhibitory activity toward ABCB1 and ABCC1 yielded a high selectivity toward ABCG2

77 sed expression of ABCB5, along with enhanced ABCB1 and ABCC3 transcript expression.

78 asma membrane of CD44, the EGF receptor, the ABCB1 and ABCG2 drug transporters, and the MCT4 monocarb

79 ion level or the subcellular distribution of ABCB1 and ABCG2 in the cells exposed to 3 muM of bafetin

80 study was to investigate the effects of the ABCB1 and ABCG2 inhibitor elacridar on brain uptake usin

81 The inhibition of ABCB1 and ABCG2 is a promising approach to enhance brain

82 Transporters such as ABCB1 and ABCG2 limit the exposure of several anticancer

83 rst-trimester explants decreased (P < 0.001) ABCB1 and ABCG2 mRNA and protein levels.

84 Bafetinib significantly sensitized ABCB1 and ABCG2 overexpressing MDR cells to their antica

85 When Abcb1 and Abcg2 were disrupted in mice, brain uptake of

86 gnificantly decreases the efflux activity of ABCB1 and ABCG2, but has no significant effects on ABCC1

87 denafil inhibits the transporter function of ABCB1 and ABCG2, with a stronger effect on ABCB1.

88 obiliary excretion, which may be mediated by ABCB1 and ABCG2.

89 arvested for immunohistochemical analysis of ABCB1 and Abeta levels.

90 iated with lowered gene expression of ABCG2, ABCB1 and AKR1C1.

91 dergone percutaneous intervention, when both ABCB1 and CYP2C19 are taken into account, nearly half of

92 studies are necessary to define the role of ABCB1 and IL-10 polymorphisms on SRL-induced dyslipidemi

93 ABCB1-, or ABCG2-overexpressing cells to non-ABCB1 and non-ABCG2 substrate drugs, nor did sildenafil

94 n19) transporter functions coordinately with ABCB1 and PIN1 to motivate long-distance transport of th

95 three recurrent mutated genes in OAC: TP53, ABCB1 and SEMA5A, not present in FLO-1 or OE33.

96 inding cassette transporters P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) are

97 n and functional activity of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) effl

98 cause of efflux transport by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2), the

99 s P-glycoprotein (P-gp, official gene symbol ABCB1) and breast cancer resistance protein (BCRP, offic

100 g the drug efflux pump P-glycoprotein (P-gp, ABCB1) and MRP1 (ABCC1).

101 P and screened against P-glycoprotein (P-gp, ABCB1) and multidrug resistance protein 1 (MRP1, ABCC1)

102 lopramide transport by P-glycoprotein (P-gp; ABCB1) and the breast cancer resistance protein (BCRP; A

103 ioid receptor (OPRM1), multidrug resistance (ABCB1), and catechol-o-methyltransferase (COMT) genes ar

104 ionships between 22 polymorphisms in CYP2B6, ABCB1, and CYP3A5; plasma efavirenz exposure; and/or tre

105 ABCG2, ABCB1, and possibly other transporters influence in vivo

106 ) and drug metabolism and transport (CYP3A5, ABCB1, and PXR) were analyzed in kidney transplant recip

107 our study indicated that bafetinib reversed ABCB1- and ABCG2-mediated MDR by blocking the drug efflu

108 was found to have inhibitory effects on both ABCB1- and ABCG2-mediated MDR in this in-vitro investiga

109 hate-binding cassette subfamily B, member 1 [ABCB1]) and breast cancer resistance protein (adenosine

110 ymorphisms in CACNA1G, CACNA1H, CACNA1I, and ABCB1 are associated with differential short-term seizur

111 ry new drug is now screened for transport by ABCB1, as this limits oral availability and penetration

112 nt transcriptional fusion partners involving ABCB1, as well as patients with multiple distinct fusion

113 n, the thienopyrimidine could also sensitize ABCB1- as well as ABCG2-overexpressing cells toward daun

114 Bafetinib stimulated ABCB1 ATPase activities while inhibited ABCG2 ATPase act

115 igations revealed that sildenafil stimulated ABCB1 ATPase activity and inhibited photolabeling of ABC

116 bsequent research showed that Dw3 encodes an ABCB1 auxin transporter and Dw1 encodes a highly conserv

117 were resistant to paclitaxel, a substrate of ABCB1, both in vitro and in vivo.

118 Significantly lower expression of ABCB1 but not ABCC4 or ABCG2 was found following exposur

119 selectively blocking the efflux function of ABCB1, but not interfering with the expression level and

120 Dynamic induction of ABCB1 by diverse stressors, including chemotherapy, faci

121 binding domains of sea urchin versus murine ABCB1 by mutation of Sp-ABCB1a and treatment of embryos

122 telet aggregation values were similar across ABCB1 C3435T genotypes (P=0.73).

123 ABCB1 C3435T genotypes did not influence the antiplatele

124 No significant influence of ABCB1 C3435T genotypes on the occurrence of ST was found

125 this study was to assess the association of ABCB1 C3435T genotypes with the antiplatelet efficacy of

126 Routine genotyping of ABCB1 C3435T polymorphisms should not be recommended for

127 ous coronary intervention were genotyped for ABCB1 C3435T, and ADP-induced platelet aggregation was a

128 taxel in P-gp-expressing SW620/Ad300 and HEK/ABCB1 cell lines.

129 ecause drug pumps like P-glycoprotein (P-gp, ABCB1) confer multidrug resistance and mutant ABC protei

130 re observed, but the specific involvement of ABCB1 could not be confirmed in these pathways.

131 human ATP-binding-cassette (ABC) transporter ABCB1, coupling of drug-binding by the two transmembrane

132 cancerous cells alike, attempts at targeting ABCB1 directly have failed due to low specificity and di

133 on: Our results show for the first time that ABCB1 does not solely account for the "barrier" property

134 lines, and they were not substrates for the ABCB1 drug efflux transporter.

135 carcinoma cell line known to overexpress the ABCB1 drug transporter and was also unaffected by overex

136 The P-glycoprotein (P-gp, ABCB1) drug pump protects us from toxic compounds and co

137 a MDR1/A retrovirus overexpressing the human ABCB1 efflux pump (MDR cell line).

138 ABCB1 encodes Multidrug Resistance protein (MDR1), an AT

139 he influence of the CYP3A4*22, CYP3A5*3, and ABCB1 exons 12, 21, and 26 polymorphisms in donors and r

140 MT expressing glioblastoma (T98G) and a high ABCB1 expressing triple-negative breast cancer cell line

141 ABCB1 expression and activity were found to be decreased

142 ABCB1 expression and activity were found to be decreased

143 ABCB1 expression correlated with ICEC0942 and THZ1 respo

144 the pronounced species differences in ABCG2/ABCB1 expression ratios at the BBB.

145 amage responses, and to upregulate ABCG2 and ABCB1 expression, which therefore increased the cross-re

146 ABC subfamily B member 1 (ABCB1) expression was reduced, and ABCC-mediated efflux

147 pramide in humans to elucidate the impact of ABCB1 function on its brain kinetics.

148 Convergent evolution of ABCB1 fusion is therefore frequent in chemotherapy resis

149 The ABCB1 gene encodes P-glycoprotein, which limits brain co

150 ingle nucleotide polymorphisms (SNPs) of the ABCB1 gene encoding P-gp (C1236T, G2677T/A, and C3435T)

151 ABCB1 gene expression was observed in 4 out of 5 paediat

152 vity of the developed biosensor in detecting ABCB1 gene in genomic samples.

153 ses to SRL treatment, confirming the role of ABCB1 gene in SRL pharmacokinetics and pharmacodynamics.

154 Similarly, testing of the ABCB1 gene only correctly foretold response in 51 (48.6%

155 Abcb1 gene resulted up-regulated at 48 hpf by PS-COOH wh

156 entified in a DNA sequence mapping the human ABCB1 gene.

157 MDR1 (multidrug resistant-1), encoded by the ABCB1 gene.

158 isorder predicts poor treatment outcome, but ABCB1 genetic effects in patients with cognitive impairm

159 The authors examined ABCB1 genetic variants as predictors of remission and si

160 , Madin-Darby canine kidney cells expressing ABCB1-GFP were used as a model to investigate this mutan

161 The functional SNP rs10245483 upstream from ABCB1 had a significant effect on remission and side eff

162 The P-glycoprotein (P-gp) drug pump (ABCB1) has two transmembrane domains and two nucleotide-

163 iants of the multidrug resistance gene (MDR1/ABCB1) have been associated with increased susceptibilit

164 We show that ABCB1-I541F is not properly folded and is more susceptib

165 plasma membrane expression, and activity of ABCB1-I541F.

166 We genotyped ABCB1 in 2932 patients with acute coronary syndromes und

167 transporter P-glycoprotein (P-gp) encoded by ABCB1 in human hepatoma cells (HepG2) without modifying

168 radiotracer (11)C-metoclopramide can measure ABCB1 induction at the BBB in a beta-amyloidosis mouse m

169 Immunohistochemical analysis confirmed ABCB1 induction in the brains of PCN-treated APP/PS1-21

170 Immunohistochemical analysis confirmed ABCB1 induction in the brains of PCN-treated APP/PS1-21

171 Conclusion: (11)C-metoclopramide can measure ABCB1 induction in the mouse brain without the need to c

172 Conclusion: (11)C-metoclopramide can measure ABCB1 induction in the mouse brain without the need to c

173 l genetic variant (C3435T, rs1045642) within ABCB1 influences clopidogrel treatment efficacy; however

174 )C-metoclopramide PET scans without and with ABCB1 inhibition using cyclosporine A (CsA).

175 eukemia cells from targeted third-generation ABCB1 inhibition, providing an explanation for the failu

176 d total retinal distribution volume VTDuring ABCB1 inhibition, retinal VT and influx rate constant K1

177 etinal distribution volume VTResults: During ABCB1 inhibition, retinal VT and influx rate constant K1

178 -verapamil distribution to the retina during ABCB1 inhibition, which provides first in vivo evidence

179 -verapamil distribution to the retina during ABCB1 inhibition, which provides first in vivo evidence

180 x was significantly decreased in presence of ABCB1 inhibitor in Caco-2 cells (-20.4%; p < 0.05) and i

181 with concurrent intravenous infusion of the ABCB1 inhibitor tariquidar (3.75 mg/min, n = 5) or after

182 without and with concurrent infusion of the ABCB1 inhibitor tariquidar.

183 without and with concurrent infusion of the ABCB1 inhibitor tariquidar.

184 hermore, the strategy that co-administer MDR-ABCB1 inhibitor to overcome the resistance of one FDA ap

185 Ko143, gefitinib, and nilotinib, but not an ABCB1 inhibitor.

186 providing an explanation for the failure of ABCB1 inhibitors in clinical trials.

187 design and synthesis of a new generation of ABCB1 inhibitors, leading to further research on multidr

188 use as adjuvants to enhance the activity of ABCB1 inhibitors.

189 The drug efflux pump ABCB1 is a key driver of chemoresistance, and high expre

190 ABCB1 is a predictive marker of chemotherapy response in

191 Our aim was to explore whether ABCB1 is also involved in vitamin K efflux.

192 MDR1/ABCB1 is an interesting candidate gene for IBD.

193 Overall, we showed for the first time that ABCB1 is involved in enterocyte vitamin K efflux in both

194 Drug efflux pump ABCB1 is overexpressed in chemoresistant neoplasms where

195 A proposed method to inhibit ABCB1 is to target its cancer-specific, upstream regulat

196 P-glycoprotein (P-gp, ABCB1) is a member of the ATP-binding cassette (ABC) tra

197 P-glycoprotein (P-gp; ABCB1) is an ABC drug pump that protects us from toxic c

198 P-glycoprotein (P-gp, ABCB1) is an ATP-binding cassette drug pump that protect

199 multidrug transporter P-glycoprotein (P-gp, ABCB1) is an ATP-dependent pump that mediates the efflux

200 P-glycoprotein (P-gp, ABCB1) is an important part of the multixenobiotic resis

201 P-glycoprotein (ABCB1) is expressed at the blood-retina barrier (BRB), w

202 P-glycoprotein (P-gp), also known as ABCB1, is a cell membrane transporter that mediates the

203 CYP2C19, but not PON1 or ABCB1, is a significant determinant of the pharmacodynam

204 nce identity with the multidrug transporter, ABCB1, its N-terminal domain is poorly conserved, leadin

205 positive correlation between k (E,brain) and ABCB1 levels in the brain.

206 tive correlation between kE,brain values and ABCB1 levels in the brain.

207 ms (SNPs) across five genes: CYP3A4, CYP3A5, ABCB1 (MDR1; encoding P-glycoprotein), NR1I2 (encoding t

208 administration of a TLR2 ligand, preserving ABCB1/MDR1 p-gp expression.

209 nduced synthesis and drug efflux activity of ABCB1/MDR1 p-gp in murine and human CD11b(+)-myeloid cel

210 biotic defense via the multidrug transporter ABCB1/MDR1 p-gp.

211 or ABCB1-TWD1 interactions and activation of ABCB1-mediated auxin transport by TWD1.

212 rase reporter gene assay and in decreases in ABCB1-mediated efflux of rhodamine 123.

213 TTT-28 reversed the ABCB1-mediated MDR and increased the accumulation of [(3

214 hiazole-valine peptidomimetic, could reverse ABCB1-mediated MDR in vitro and in vivo.

215 Graviquinone bypassed ABCB1-mediated resistance, induced DNA damage in lung ca

216 erately potent, competitive inhibitor of the ABCB1-mediated transport of calcein AM, and noncompetiti

217 tte (ABC) transporter, P-glycoprotein (P-gp; ABCB1), mediates the ATP-dependent efflux of a variety o

218 n K postprandial response was higher in male Abcb1(-/-) mice after gavage compared to control animals

219 In lamotrigine subjects, 1 ABCB1 missense polymorphism (rs2032582/S893A; p = 0.015,

220 f MDR cells with 1 led to instability of the ABCB1 mRNA and consequently a reduction in P-gp protein,

221 e ATP-binding cassette subfamily B member 1 (ABCB1) multidrug transporter P-glycoprotein plays a cent

222 at the blood-brain barrier, P-glycoprotein (ABCB1), multidrug resistance associated protein 4 (ABCC4

223 embrane efflux pumps such as P-glycoprotein (ABCB1), multidrug resistance protein 1 (ABCC1), and brea

224 P-Glycoprotein (P-gp, ABCB1), multidrug resistance-associated protein 1 (MRP1,

225 er [P-glycoprotein, ATP binding cassette b1 (Abcb1); multidrug resistance-associated protein-2 (Mrp2)

226 nobiotic metabolism, including a decrease in ABCB1/multidrug resistance (MDR)1 p-glycoprotein (p-gp)

227 ide binding domain and linker of Arabidopsis ABCB1, mutations of which do not alter ABCB1 protein sta

228 he I541F mutation, when reproduced either in ABCB1 or in ABCB4, led to retention in the endoplasmic r

229 ssette family like the human P-glycoprotein (ABCB1 or Pgp) are responsible for many failed cancer and

230 l did not alter the sensitivity of parental, ABCB1-, or ABCG2-overexpressing cells to non-ABCB1 and n

231 sed the accumulation of [(3)H]-paclitaxel in ABCB1 overexpressing cells by selectively blocking the e

232 cularly doxorubicin and [(3)H]-paclitaxel in ABCB1 overexpressing cells; mitoxantrone and [(3)H]-mito

233 s, thereby potently inhibiting the growth of ABCB1 overexpressing tumors.

234 In ABCB1-overexpressing cell lines, HG-829 significantly en

235 In ABCB1-overexpressing cells, nontoxic doses of sildenafil

236 the profound effect of the drug-transporting ABCB1 P-glycoprotein on the pharmacokinetics of drugs in

237 action demonstrated that lenalidomide was an ABCB1 (P-glycoprotein [P-gp]) substrate.

238 g docetaxel response, despite an increase in Abcb1 (P-glycoprotein) expression that was sufficient to

239 -binding cassette (ABC) transporters such as ABCB1 (P-glycoprotein), ABCC1 (MRP1), and ABCG2 (BCRP) a

240 ABCB1 (P-glycoprotein/MDR1) is a multidrug efflux transp

241 in vitro data indicating lenalidomide was an ABCB1 (P-gp) substrate.

242 ulators of the membrane transporter proteins ABCB1 (P-gp), ABCG2 (BCRP), and ABCC1 (MRP1), which are

243 r multiple transcriptional fusions involving ABCB1, placing it under the control of a strong promoter

244 P-glycoprotein (ABC subfamily B member 1, ABCB1) plays an important role at the blood-brain barrie

245 P-glycoprotein (ABCB1) plays an important role at the blood-brain barrie

246 ABCB1 polymorphisms were found to be associated with lip

247 own disease, polymorphisms (CYP2C19, CYP3A5, ABCB1, PON1), noncompliance, co-medications, diet, smoki

248 We demonstrate that ABCB1 positive patients from an infant chemotherapy-led

249 ABCB1 positivity also correlated with reduced event free

250 ted in lower transcriptional activity of the ABCB1 promoter as judged from the luciferase reporter ge

251 opsis ABCB1, mutations of which do not alter ABCB1 protein stability or location but do affect its tr

252 Wnt3a reversed the Abeta-induced changes to ABCB1 protein.

253 PET with avid substrates of P-glycoprotein (ABCB1) provided evidence of the role of this efflux tran

254 icroscopy structure of substrate-bound human ABCB1 reconstituted in lipidic nanodiscs, revealing a si

255 Cyclosporin A, a competitive substrate for ABCB1, restored maturation, plasma membrane expression,

256 induces MDR1 gene and P-glycoprotein (P-gp, ABCB1), resulting in a multidrug-resistant phenotype.

257 structure of inhibited, human-mouse chimeric ABCB1 revealed two molecules of zosuquidar occupying the

258 rodents, Abcg2) and P-glycoprotein (humans, ABCB1; rodents, Abcb1a/b) affects tissue distribution an

259 A decreased risk was found with ABCB1 rs1045642 (OR, 0.79; 95% CI, 0.71-0.89; FDR-P = 0.

260 sporters such as P-glycoprotein (P-gp; MDR1, ABCB1), significantly less is known regarding its intera

261 sociated with trough concentrations, and the ABCB1 single-nucleotide polymorphism rs4148738 and the C

262 The authors genotyped 10 ABCB1 single-nucleotide polymorphisms (SNPs) in 683 pati

263 ences between substrate- and inhibitor-bound ABCB1 sites are amplified toward the nucleotide-binding

264 Associations with the ABCB1 SNPs were not significant.

265 We also show ROR1 regulates ABCB1 stability and transcription via MAPK/ERK and p53.

266 We performed PET with the weak ABCB1 substrate (11)C-metoclopramide in humans to elucid

267 We performed PET scans with the ABCB1 substrate (R)-(11)C-verapamil on 5 healthy male vo

268 Methods: We performed PET scans with the ABCB1 substrate (R)-(11)C-verapamil on 5 healthy male vo

269 the effective intracellular concentration of ABCB1 substrate drugs such as paclitaxel.

270 was to investigate whether PET with the weak ABCB1 substrate radiotracer (11)C-metoclopramide can mea

271 This may not reflect the situation for weak ABCB1 substrates including several antidepressants, anti

272 nd penetration into sanctuaries protected by ABCB1, such as the brain.

273 Genetic variants in ABCB1, TGFB1, and XRCC1 appear to be associated with sus

274 high-affinity substrates for p-glycoprotein (ABCB1), the multidrug resistance protein known to facili

275 sequencing to assay mutations in CYP2C19 and ABCB1, the two genes genetically linked to respond.

276 ponse-like transcriptional program to induce ABCB1 through remodeling and activation of an ATF4-bound

277 In contrast, poly(I:C) decreased (P < 0.05) ABCB1, TLR-3, and TLR-4 mRNA levels in the third trimest

278 We found that the ability of ABCB1 to prevent accumulation of some drugs in the brain

279 rs that could identify tumors with increased Abcb1 transcript levels.

280 n, which provides first in vivo evidence for ABCB1 transport activity at the human BRB.

281 n, which provides first in vivo evidence for ABCB1 transport activity at the human BRB.

282 : Four T-type calcium channel variants and 1 ABCB1 transporter variant were associated with different

283 the efflux of rhodamine 123 mediated by the ABCB1 transporter.

284 and evaluated a novel selective inhibitor of ABCB1 (TTT-28) with high efficacy and low toxicity.

285 used to verify specific ABC transporter B1 (ABCB1)-TWD1 interaction.

286 The D/E-P1008 motif is also important for ABCB1-TWD1 interactions and activation of ABCB1-mediated

287 Remarkably, both ABCB1 upregulation and doxorubicin resistance caused by

288 We have identified ABCB1 upregulation as a common mechanism of resistance t

289 Functional inhibition of ABCB1 using vardenafil or verapamil significantly (p <=

290 In conclusion, these data suggest that an ABCB1 variant known to alter protein expression represen

291 ABCB1 variation has been associated with antidepressant

292 Stress-induced upregulation of ABCB1 was mitigated by combined use of the pharmacologic

293 Finally, a reliable calibration curve of ABCB1 was obtained with an experimental detection limit

294 The auxin transport activity of ABCB1 was suggested to be regulated by a physical intera

295 ABCB1 was upregulated in ICEC0942-resistant cells and th

296 lut-1), and permeability-glycoprotein (p-GP, ABCB1) were similarly significantly higher in the CN wit

297 elapse SNPs, including variants in PDE4B and ABCB1, were also associated with antileukemic drug pharm

298 ansporter P-glycoprotein (Pgp; also known as ABCB1), which has a central role in the clearance of xen

299 the multidrug-resistance efflux transporter ABCB1, which is frequently expressed in resistant neurob

300 Pase activity and inhibited photolabeling of ABCB1 with [(125)I]-iodoarylazidoprazosin (IAAP), wherea